CANCELLED Long-term Vector-mediated Delivery of anti-HIV Monoclonal Antibodies for Treatment and Prevention
Ronald C Desrosiers
Professor of Pathology University of Miami Miller School of Medicine, Miami, USA
Host: Bonaventura Clotet, IrsiCaixa
Date and time: | 12.00
Venue: Auditorium, IJC Building, Campus Can Ruti
We are sorry but this seminar has been CANCELLED for reasons outside our control. We will try to reschedule it next year.
Professor Ronald Derosiers is a highly respected figure in the field of viral research and, among many other contributions, has been credited with the discovery of the simian homologs of human immunodeficiency and human herpesviruses, including oncogenic pathogens. His group is leading the way towards induction of a protective sterilizing barrier against SIV/HIV using recombinant gamma-2 herpesvirus vaccine approaches and AAV-vectored delivery of potent broadly-neutralizing antibodies.Professor Ronald Derosiers is a renowned researcher in the field of virology and HIV, his research has focussed particularly on the discovery of new simian viruses and their development into new models of human disease.
Professor Derosiers is the leader of the team that described the discovery of the simian immunodeficiency virus and its association with AIDS in rhesus monkeys in a seminal Science paper just one year after the first descriptions of HIV-1 in humans with AIDS. Other important discoveries include of a gamma-2 herpesvirus of rhesus monkeys that is a close homolog of the oncogenic human Kaposi sarcoma herpesvirus (KSHV) and new type D retroviruses that are a major cause of morbidity and mortality in macaque monkey colonies.
During his distinguished career, Professor Derosiers' group has made many breakthroughs. They were the first to define an infectious, pathogenic, molecular clone of SIV, the first of its kind for any HIV, SIV, or any lentivirus. This SIVmac239 is still viral isolate of choice for most monkey studies of SIH/HIV and is widely used around the world. He and his team worked extensively on deletions of the six so-called "auxiliary" genes of the immunodeficiency virus in cell culture and in experimental infection of rhesus monkeys. Subsequent collaborations with clinical scientists at UMass Medical School allowed his team to identify the first case of a HIV long-term non-progressors infected with a Nef deleted variant, leading eventually to the description of the Sydney cohort comprised of individuals infected with similar Nef deleted viruses. This has spurred great interest in developing attenuated life viral vaccines for HIV; still one of the most effective approaches to date in SIV animal models.
A good portion of the effort in the Desrosiers lab at the current time is directed to defining ways by which a protective sterilizing immunity may be induced against SIV/HIV. The current focus is on two approaches: the recombinant gamma-2 RRV herpesvirus and use of specifically tailored AAV vectors to deliver persistent levels of potent broadly-neutralizing antibodies.
Professor Desrosiers has been a strong advocate for the need for more basic discovery research in the search for an AIDS vaccine, and less government-funded product development, product manufacturing and clinical testing.
This seminar will be introduced by
Bonaventura Clotet, Director, IrsiCaixa AIDS Research Institute; President, Fight AIDS Foundation